Joel Baumgartner, MD
Dr. Joel Baumgartner is a surgical oncologist and Associate Professor of Clinical Surgery at the University of California at San Diego and its Moore’s Comprehensive Cancer Center. He has expertise in the treatment of tumors that have metastasized to the abdomen and peritoneal surface malignancies like malignant peritoneal mesothelioma and is particularly skilled in an innovative treatment that combines cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. He also treats melanoma and performs wide local excision of these tumors, sentinel lymph node biopsies, and lymph node dissections.[1]
Education and Career
Dr. Baumgartner attended Purdue University in West Lafayette, Indiana as an undergraduate. After earning a Bachelor of Science degree in Biology, he attended Indiana University School of Medicine in Bloomington and then completed his internship and residency in General Surgery at the University of Colorado in Aurora, Colorado. He then completed a surgical oncology fellowship at the University of Pittsburgh School of Medicine with a focus on clinical research, which included additional training in the development and conduct of clinical trials.[1]
Dr. Baumgartner’s years at the University of Pittsburgh played an integral role in his expertise in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: the facility boasts one of the highest volume HIPEC centers in the world.
Professional Memberships
Dr. Baumgartner is a member of numerous societies including the Society of Surgical Oncology and the American Society of Clinical Oncology and is an associate member of the American Association for Cancer Research and the American College of Surgeons.[1]
Research
Dr. Baumgartner is actively involved in clinical trials studying the impact of hyperthermic intraperitoneal chemotherapy, the use of immunotherapy to treat cancer, and improved outcomes for melanoma.
Dr. Baumgartner’s recent publications include:[1]
- ASO Visual Abstract: Neighborhood Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy. Ann Surg Oncol. 2023 12; 30(13):8178-8179. Winicki NM, Radomski SN, Florissi IS, Cloyd JM, Gutta G, Grotz TE, Scally CP, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Kothari AN, Maduekwe UN, Patel SH, Wilson GC, Schwartz P, Varley PR, Raoof M, Lee B, Malik I, Johnston FM, Greer JB. PMID: 37768415.
- Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy. J Surg Res. 2024 01; 293:403-412. Florissi I, Radomski SN, Shou B, Cloyd JM, Kim A, Grotz T, Fournier K, Baumgartner JM, Lambert L, Abbott DE, Schwartz P, Staley CA, Clarke C, Dineen S, Patel SH, Wilson GC, Raoof M, Johnston FM, Greer JB. PMID: 37806228.
- Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy. Ann Surg Oncol. 2023 Nov; 30(12):7840-7847. Winicki NM, Radomski SN, Florissi IS, Cloyd JM, Gutta G, Grotz TE, Scally CP, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Kothari AN, Maduekwe UN, Patel SH, Wilson GC, Schwartz P, Varley PR, Raoof M, Lee B, Malik I, Johnston FM, Greer JB. PMID: 37620532; PMCID: PMC10592201.
- Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases. J Gastrointest Cancer. 2023 Jul 12. Baumgartner JM, Botta GP. PMID: 37436640.
- ASO Visual Abstract: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC? Ann Surg Oncol. 2023 Feb; 30(2):776. Khan S, Doan NH, Hosseini M, Kelly K, Veerapong J, Lowy AM, Baumgartner J. PMID: 36369408.
- Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis. Surg Endosc. 2023 07; 37(7):5644-5651. Cho CY, Veerapong J, Baumgartner JM, Murphy JD, Lowy AM, Kelly KJ. PMID: 36477643; PMCID: PMC10322763.
- Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC. J Surg Oncol. 2023 Mar; 127(4):706-715. Kubi B, Nudotor R, Fackche N, Rowe J, Cloyd JM, Ahmed A, Grotz TE, Fournier K, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB. PMID: 36468401.
